IP Library › Granted Patent US 12,364,807
Granted Patent B2
US 12,364,807 · App. 17/975,112 · Granted Jul 22, 2025

System and method for maximum insulin pump bolus override

Inventor: John Walsh (San Diego, CA)
Assignee: Tandem Diabetes Care, Inc.
A61M5/14244A61M5/168A61M5/1723G16H20/17G16H40/63A61M2205/18A61M2205/3569A61M2205/3576A61M2205/502
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,364,807
App. No.
17/975,112
Granted
Jul 22, 2025
Kind
B2
Abstract

An ambulatory infusion pump can include a maximum bolus override procedure. When a bolus amount greater than a maximum bolus amount is requested, the ambulatory infusion pump can provide an alert indicating that the bolus amount requested exceeds the maximum bolus amount. If a user confirms the request in response to the alert, the bolus amount can be delivered to the user. The bolus amount delivered in response to the confirmation can be a first portion of the bolus amount. A reminder can then be provided that a second portion of the bolus amount that is a remaining portion of the requested bolus amount was also requested. If a second confirmation is received in response to the alert, the second portion of the bolus amount can also be delivered to the user.

Claims (47)

1. An ambulatory infusion pump system, comprising:

a delivery mechanism adapted to facilitate a delivery of insulin to a user;

a user interface adapted to receive input data from the user;

a memory adapted to store a maximum bolus limit defining a maximum bolus amount the user can operate a pump including the delivery mechanism to deliver at any one time; and

at least one processor operably connected to the delivery mechanism, the user interface and the memory, the at least one processor adapted to execute a maximum bolus override procedure when the user manually enters a request for a delivery of a single, user-requested bolus amount greater than the maximum bolus limit through the user interface, the maximum bolus override procedure comprising:

providing a first alert on the user interface warning the user that the single, user-requested bolus amount in the request exceeds the maximum bolus limit;

receiving a first confirmation of the request in response to the first alert;

causing the delivery mechanism to deliver a first portion of the single, user-requested bolus amount, the first portion being no more than the maximum bolus limit;

after the first portion of the single, user-requested bolus amount is delivered to the user, providing a second alert on the user interface reminding the user that a second portion of the single, user-requested bolus amount comprising a remainder of the single, user-requested bolus amount was requested;

receiving a second confirmation to deliver the second portion of the single, user-requested bolus amount; and

causing the delivery mechanism to deliver the second portion of the single, user-requested bolus amount to the user in response to the second confirmation.

2. The ambulatory infusion pump system of claim 1 , wherein the first portion of the single, user-requested bolus amount is equal to the maximum bolus limit.

3. The ambulatory infusion pump system of claim 1 , wherein the first portion of the single, user-requested bolus amount is a predetermined percentage of the single, user-requested bolus amount.

4. The ambulatory infusion pump system of claim 1 , wherein the user interface is adapted to enable the user to set the maximum bolus limit.

5. The ambulatory infusion pump system of claim 4 , wherein the memory stores a maximum value for the maximum bolus limit, and the at least one processor is further adapted to inhibit the user from setting the maximum bolus limit above the maximum value.

6. The ambulatory infusion pump system of claim 1 , wherein the first portion of the single, user-requested bolus amount is not delivered if the first confirmation is not received within a predetermined period of time.

7. The ambulatory infusion pump system of claim 1 , wherein the first portion of the single, user-requested bolus amount is automatically delivered if the first confirmation is not received within a predetermined period of time.

8. The ambulatory infusion pump system of claim 1 , wherein the second portion of the single, user-requested bolus amount is not delivered if the second confirmation is not received within a predetermined period of time.

9. The ambulatory infusion pump system of claim 1 , wherein the first alert and the second alert each further include at least one of an audio alert and a tactile alert.

10. An ambulatory infusion pump system, comprising:

a delivery mechanism adapted to facilitate a delivery of insulin to a user;

a user interface adapted to receive input data from the user;

a memory adapted to store a maximum bolus limit defining a maximum bolus amount the user can operate a pump including the delivery mechanism to deliver at any one time; and

at least one processor operably connected to the delivery mechanism, the user interface and the memory, the at least one processor configured to:

provide a first alert on the user interface warning the user that a single, user-requested bolus amount in a request exceeds the maximum bolus limit;

receive a first confirmation of the request in response to the first alert through the user interface;

cause the delivery mechanism to deliver a first portion of the single, user-requested bolus amount to the user in response to the first confirmation, the first portion being no more than the maximum bolus limit;

after the first portion of the single, user-requested bolus amount is delivered to the user, provide a second alert on the user interface reminding the user that a second portion of the single, user-requested bolus amount comprising a remainder of the single, user-requested bolus amount was requested;

receive a second confirmation through the user interface to deliver the second portion of the single, user-requested bolus amount; and

cause the delivery mechanism to deliver the second portion of the single, user-requested bolus amount to the user in response to the second confirmation.

11. The ambulatory infusion pump system of claim 10 , wherein the first portion of the single, user-requested bolus amount is equal to the maximum bolus limit.

12. The ambulatory infusion pump system of claim 10 , wherein the first portion of the single, user-requested bolus amount is a predetermined percentage of the single, user-requested bolus amount.

13. The ambulatory infusion pump system of claim 10 , wherein the user interface is adapted to permit the user to set the maximum bolus limit.

14. The ambulatory infusion pump system of claim 13 , wherein the memory stores a maximum value for the maximum bolus limit, and the at least one processor is further adapted to inhibit the user from setting the maximum bolus limit above the maximum value.

15. The ambulatory infusion pump system of claim 10 , wherein the first alert and the second alert each further include at least one of an audio alert and a tactile alert.

16. An ambulatory infusion pump system, comprising:

a delivery mechanism adapted to facilitate a delivery of insulin to a user;

a user interface adapted to receive input data from the user; and

at least one processor operably connected to the delivery mechanism and the user interface, the at least one processor configured to:

determine that an amount of a user programmed bolus is greater than a maximum bolus amount that the user is enabled to operate a pump including the delivery mechanism to deliver at any one time;

automatically divide the amount of the user programmed bolus into a first portion and a second portion, the first portion being no more than the maximum bolus amount;

deliver the first portion of the amount of the user programmed bolus to the user;

provide a reminder that the second portion of the amount of the user programmed bolus is remaining; and

deliver the second portion of the amount of the user programmed bolus to the user upon receiving a confirmation in response to the reminder.

17. The ambulatory infusion pump system of claim 16 , wherein the first portion of the amount of the user programmed bolus is equal to the maximum bolus amount.

18. The ambulatory infusion pump system of claim 16 , wherein the first portion of the amount of the user programmed bolus is a predetermined percentage of the amount of the user programmed bolus.

19. The ambulatory infusion pump system of claim 16 , wherein the second portion of the amount of the user programmed bolus is not delivered if the confirmation is not received within a predetermined period of time.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2023
From: WALSH, JOHN
To: TANDEM DIABETES CARE, INC.
Reel/Frame 062614/0411 →
Continuity (3)
Continuation 15948368 · Apr 9, 2018
Continuation 13800387 · Mar 13, 2013
Related Publication 20230047136A1 · Feb 16, 2023
References Cited (80)
US 4529401A · Leslie et al. · 1985 [cited by applicant]
US 4731051A · Fischell · 1988 [cited by applicant]
US 6687546B2 · Lebel et al. · 2004 [cited by applicant]
US 6758810B2 · Lebel et al. · 2004 [cited by applicant]
US 6811533B2 · Lebel et al. · 2004 [cited by applicant]
US 6813519B2 · Lebel et al. · 2004 [cited by applicant]
US 6981967B2 · Massengale et al. · 2006 [cited by applicant]
US 6999854B2 · Roth · 2006 [cited by applicant]
US 7008413B2 · Kovach et al. · 2006 [cited by applicant]
US 7024245B2 · Lebel et al. · 2006 [cited by applicant]
US 7347819B2 · Lebel et al. · 2008 [cited by applicant]
US 7369635B2 · Spital et al. · 2008 [cited by applicant]
US 7704226B2 · Mueller, Jr. et al. · 2010 [cited by applicant]
US 7806854B2 · Damiano et al. · 2010 [cited by applicant]
US 7941200B2 · Weinert et al. · 2011 [cited by applicant]
US 8234128B2 · Martucci et al. · 2012 [cited by applicant]
US 8287495B2 · Michaud · 2012 [cited by applicant]
US 8414563B2 · Karmen et al. · 2013 [cited by applicant]
US 8573027B2 · Rosinko · 2013 [cited by applicant]
US 9474856B2 · Morales · 2016 [cited by applicant]
US 9492608B2 · Saint · 2016 [cited by applicant]
US 9603995B2 · Rosinko et al. · 2017 [cited by applicant]
US 9737656B2 · Rosinko · 2017 [cited by applicant]
US 9940441B2 · Walsh · 2018 [cited by examiner]
US 10016561B2 · Saint et al. · 2018 [cited by applicant]
US 20010037083A1 · Hartlaub et al. · 2001 [cited by applicant]
US 20030060765A1 · Campbell et al. · 2003 [cited by applicant]
US 20050020996A1 · Hartlaub et al. · 2005 [cited by applicant]
US 20050022274A1 · Campbell et al. · 2005 [cited by applicant]
US 20050137530A1 · Campbell et al. · 2005 [cited by applicant]
US 20070118405A1 · Campbell et al. · 2007 [cited by applicant]
US 20090005729A1 · Hendrixson · 2009 [cited by applicant]
US 20090043290A1 · Villegas et al. · 2009 [cited by applicant]
US 20090088731A1 · Campbell · 2009 [cited by examiner]
US 20100008795A1 · DiPerna · 2010 [cited by applicant]
US 20100057057A1 · Hayter · 2010 [cited by applicant]
US 20100160740A1 · Cohen et al. · 2010 [cited by applicant]
US 20100161236A1 · Cohen et al. · 2010 [cited by applicant]
US 20100161346A1 · Getschmann et al. · 2010 [cited by applicant]
US 20100174553A1 · Kaufman et al. · 2010 [cited by applicant]
US 20100262434A1 · Shaya · 2010 [cited by applicant]
US 20100298685A1 · Hayter et al. · 2010 [cited by applicant]
US 20100305965A1 · Benjamin et al. · 2010 [cited by applicant]
US 20110004189A1 · Vaidya et al. · 2011 [cited by applicant]
US 20110021898A1 · Wei et al. · 2011 [cited by applicant]
US 20110040247A1 · Mandro et al. · 2011 [cited by applicant]
US 20110098548A1 · Budiman et al. · 2011 [cited by applicant]
US 20110106049A1 · Damiano et al. · 2011 [cited by applicant]
US 20110124996A1 · Reinke et al. · 2011 [cited by applicant]
US 20110130746A1 · Budiman · 2011 [cited by applicant]
US 20110152770A1 · DiPerna et al. · 2011 [cited by applicant]
US 20110184653A1 · Ray et al. · 2011 [cited by applicant]
US 20110224523A1 · Budiman · 2011 [cited by applicant]
US 20110320049A1 · Chossat et al. · 2011 [cited by applicant]
US 20120029468A1 · DiPerna et al. · 2012 [cited by applicant]
US 20120330227A1 · Budiman et al. · 2012 [cited by applicant]
US 20130053816A1 · DiPerna · 2013 [cited by applicant]
US 20130121630A1 · Blomquist · 2013 [cited by applicant]
US 20130283196A1 · Farnan et al. · 2013 [cited by applicant]
US 20130332874A1 · Rosinko et al. · 2013 [cited by applicant]
US 20140012511A1 · Mensinger et al. · 2014 [cited by applicant]
US 20140276420A1 · Rosinko · 2014 [cited by applicant]
US 20140276553A1 · Rosinko et al. · 2014 [cited by applicant]
US 20140276556A1 · Saint et al. · 2014 [cited by applicant]
US 20150182693A1 · Rosinko · 2015 [cited by applicant]
US 20150182695A1 · Rosinko · 2015 [cited by applicant]
US 20150217044A1 · Blomquist · 2015 [cited by applicant]
US 20150314062A1 · Blomquist et al. · 2015 [cited by applicant]
US 20160082188A1 · Blomquist et al. · 2016 [cited by applicant]
US 20160317743A1 · Estes · 2016 [cited by applicant]
US 20170165416A1 · Saint · 2017 [cited by applicant]
US 20170246380A1 · Rosinko et al. · 2017 [cited by applicant]
US 20180021514A1 · Rosinko · 2018 [cited by applicant]
US 20180133398A1 · Blomquist · 2018 [cited by applicant]
WO 2013184896A1 · 2013 [cited by applicant]
Communication dated May 15, 2020 for EP Application No. 14 774 4499.9, 6 pages. [cited by applicant]
Application and File history for U.S. Appl. No. 13/800,387, filed Mar. 13, 2013. Inventors: Walsh et al. [cited by applicant]
Search Report dated Oct. 6, 2016 for EP Application No. 14774499.9, 10 pages. [cited by applicant]
Search Report and Written Opinion dated Jun. 9, 2014 for PCT Application No. PCT/US2014/018856 filed February 267, 2014, 12 pages. [cited by applicant]
Internation Search report and Written Opinion for PCT/US2014/018850 dated May 7, 2014. [cited by applicant]